跳到主要內容

臺灣博碩士論文加值系統

(44.210.149.205) 您好!臺灣時間:2024/04/12 22:44
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:侯惠琦
研究生(外文):HOU, HUI-CHI
論文名稱:探討ADAM17在神經膠質母細胞瘤對於替莫唑胺的敏感性角色
論文名稱(外文):To explore the role of ADAM17 in temozolomide sensitivity of glioblastoma
指導教授:陳瑞傑
指導教授(外文):CHEN, JUI-CHIEH
學位類別:碩士
校院名稱:國立嘉義大學
系所名稱:生化科技學系研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2019
畢業學年度:108
語文別:中文
論文頁數:52
中文關鍵詞:神經膠質母細胞瘤微小核醣核酸解整合素與金屬蛋白酶17替莫唑胺
外文關鍵詞:GlioblastomaMicroRNAs(miRNAs)A disintegrin and metalloproteinase 17 (ADAM17)Temozolomide (TMZ)
相關次數:
  • 被引用被引用:0
  • 點閱點閱:116
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
中文摘要.......................................1
英文摘要.......................................2
致謝...........................................4
目次...........................................5
第一章、緒論(Introduction)....................10
一、腦瘤.......................................10
二、腦瘤分類....................................10
三、神經膠質母細胞瘤(Glioblastoma ; GBM).......12
四、替莫唑胺 (Temozolomide ; TMZ)..............13
五、腫瘤微環境因子(Tumor microenvironment factors).....14
六、微小核醣核酸 (MicroRNA;miRNA)..............14
七、解整合素與金屬蛋白酶17(ADAM17)...............16
實驗動機.........................................18
一、研究背景.....................................18
二、研究目的.....................................18
第二章、材料與方法(Materials and methods).......19
一、材料與試劑....................................19
1.1、實驗藥品與細胞...............................19
1.2、實驗室抗體...................................20
1.3、實驗室儀器...................................20
二、實驗方法......................................21
2.1、細胞培養(Cell culture).....................21
2.2、繼代培養(Subculture).......................21
2.3、冷凍細胞(Frozen cells) ....................22
2.4、解凍細胞(Thawing cells)....................22
2.5、細胞計數(Cell counts)......................22
2.6、細胞存活率分析(MTT assay)...................23
2.7、質體轉型(Plasmid transformation)...........23
2.8、質體抽取(Plasmid extraction)...............24
2.9、質體轉染 (Plasmid transfection)............24
2.10、基因敲落(Gene knockdown)..................25
2.11、西方墨點法 (Western blot).................25
2.12、細胞群落形成分析法(Colony forming assay)...26
2.13、預測目標miRNA..............................26
2.14、提取總RNA分析microRNA表達...................27
第三章、結果......................................28
一、在GBM細胞中ADAM17可能參與TMZ抗藥性..............28
二、降低ADAM17的表現會增加U87MG細胞對於TMZ的敏感性...28
三、ADAM17的高度表現促進U87MG-R細胞對於TMZ的抗藥性...29
四、分析ADAM17上游調控的miRNA分子...................30
第四章、討論.......................................31
第五章、結論.......................................33
第六章、表與圖......................................34
表一、神經膠質母細胞瘤主要特徵........................34
圖一、............................................ 35
圖二、............................................ 36
圖三、............................................ 37
圖四、............................................ 38
圖五、.............................................39
圖六、............................................ 40
圖七、.............................................41
圖八、............................................ 42
圖九、............................................ 43
圖十、............................................ 44
圖十一、...........................................45
圖十二、...........................................46
圖十三、...........................................47
參考文獻...........................................48
縮寫對照表.........................................52
1.Abbruzzese, C., et al., Drug repurposing for the treatment of glioblastoma multiforme. J Exp Clin Cancer Res, 2017. 36(1): p. 169.
2.Blissitt, P.A., Clinical practice guideline series update: care of the adult patient with a brain tumor. J Neurosci Nurs, 2014. 46(6): p. 367-8.
3.Wilson, T.A., M.A. Karajannis, and D.H. Harter, Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int, 2014. 5: p. 64.
4.Thakkar, J.P., et al., Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev, 2014. 23(10): p. 1985-96.
5.Hochberg, F., et al., Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol, 1990. 8(1): p. 55-60.
6.Frei, P., et al., Use of mobile phones and risk of brain tumours: update of Danish cohort study. Bmj, 2011. 343: p. d6387.
7.Lagorio, S. and M. Roosli, Mobile phone use and risk of intracranial tumors: a consistency analysis. Bioelectromagnetics, 2014. 35(2): p. 79-90.
8.Hardell, L., et al., Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use. Int J Oncol, 2013. 43(6): p. 1833-45.
9.Group, T.I.S.,Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol, 2010. 39(3): p. 675-94.
10.Benson, V.S., et al., Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int J Epidemiol, 2013. 42(3): p. 792-802.
11.Deltour, I., et al., Mobile phone use and incidence of glioma in the Nordic countries 1979-2008: consistency check. Epidemiology, 2012. 23(2): p. 301-7.
12.Yeldag, G., A. Rice, and A. Del Rio Hernandez, Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers (Basel), 2018. 10(12).
13.Ribeiro Franco, P.I., et al., Tumor microenvironment components: Allies of cancer progression. Pathol Res Pract, 2019: p. 152729.
14.Costa, P.M., et al., MicroRNAs in glioblastoma: role in pathogenesis and opportunities for targeted therapies. CNS Neurol Disord Drug Targets, 2015. 14(2): p. 222-38.
15.Haab, B.B., Antibody arrays in cancer research. Mol Cell Proteomics, 2005. 4(4): p. 377-83.
16.Zhang, Y., et al., Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment. Med Res Rev, 2019.(doi: 10.1002/med.21644.)
17.Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004. 116(2): p. 281-97.
18.Croce, C.M., Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 2009. 10(10): p. 704-14.
19.Simonson, B. and S. Das, MicroRNA Therapeutics: the Next Magic Bullet? Mini Rev Med Chem, 2015. 15(6): p. 467-74.
20.Lopez-Serra, P. and M. Esteller, DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene, 2012. 31(13): p. 1609-22.
21.Melo, S.A. and R. Kalluri, Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res, 2012. 18(16): p. 4234-9.
22.Calin, G.A., et al., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 2004. 101(9): p. 2999-3004.
23.Lu, J., et al., MicroRNA expression profiles classify human cancers. Nature, 2005. 435(7043): p. 834-8.
24.Calin, G.A., et al., MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A, 2004. 101(32): p. 11755-60.
25.Sacconi, A., et al., miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis, 2012. 3: p. e423.
26.Ganci, F., et al., Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol, 2013. 24(12): p. 3082-8.
27.Moller, H.G., et al., A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol, 2013. 47(1): p. 131-44.
28.Rukov, J.L., et al., Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform, 2014. 15(4): p. 648-59.
29.Lu, Y., et al., MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep, 2013. 29(1): p. 67-72.
30.Speranza, M.C., et al., NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget, 2012. 3(7): p. 723-34.
31.Ostenfeld, M.S., et al., miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene, 2010. 29(7): p. 1073-84.
32.Wang, S., et al., miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol, 2009. 34(5): p. 1461-6.
33.Fuse, M., et al., Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol, 2011. 38(4): p. 1093-101.
34.Ye, D., Z. Shen, and S. Zhou, function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res, 2019. 11: p. 969-979.
35.Doberstein, K., et al., MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia, 2013. 15(2): p. 218-30.
36.Yang, X.W., et al., miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res, 2014. 44(5): p. 551-559.
37.Liu, Y., et al., MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep, 2014. 32(5): p. 1923-30.
38.Shi, L., et al., miR-145 is a potential biomarker for predicting clinical outcome in glioblastomas. J Cell Biochem, 2018.
39.Zhao, H., et al., Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer, 2017. 16(1): p. 59.
40.Lu, Y., et al., Overexpression of miR145 in U87 cells reduces glioma cell malignant phenotype and promotes survival after in vivo implantation. Int J Oncol, 2015. 46(3): p. 1031-8.
41.Moss, M.L., et al., Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature, 1997. 385(6618): p. 733-6.
42.Grotzinger, J., I. Lorenzen, and S. Dusterhoft, Molecular insights into the multilayered regulation of ADAM17: The role of the extracellular region. Biochim Biophys Acta Mol Cell Res, 2017. 1864(11 Pt B): p. 2088-2095.
43.Scheller, J., et al., ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol, 2011. 32(8): p. 380-7.
44.Zunke, F. and S. Rose-John, The shedding protease ADAM17: Physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res, 2017. 1864(11 Pt B): p. 2059-2070.
45.Dulloo, I., S. Muliyil, and M. Freeman, The molecular, cellular and pathophysiological roles of iRhom pseudoproteases. Open Biol, 2019. 9(3): p. 190003.
46.Sommer, A., et al., Phosphatidylserine exposure is required for ADAM17 sheddase function. Nat Commun, 2016. 7: p. 11523.
47.Chalaris, A., et al., Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood, 2007. 110(6): p. 1748-55.
48.Lee, D.C., et al., TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci, 2003. 995: p. 22-38.
49.Mineo, J.F., et al., [Glioblastomas: clinical study and search for prognostic factors]. Neurochirurgie, 2002. 48(6): p. 500-9.
50.Schumacher, N. and S. Rose-John, ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer. Cancers (Basel), 2019. 11(11).( doi: 10.3390/cancers11111736.)
51.Chen, J., et al., Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway. Neurol Sci, 2015. 36(3): p. 435-40.
52.Zheng, X., et al., ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog, 2012. 51(2): p. 150-64.
53.Chen, X., et al., ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res, 2013. 1538: p. 151-8.
54.Chen, X., et al., ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells. Neurosci Lett, 2013. 537: p. 44-9.
55.Zheng, X., et al., Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett, 2008. 265(2): p. 177-87.
56.Pillai, R.S., MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 2005. 11(12): p. 1753-61.
57.Zamore, P.D. and B. Haley, Ribo-gnome: the big world of small RNAs. Science, 2005. 309(5740): p. 1519-24.
58.Brennecke, J., et al., Principles of microRNA-target recognition. PLoS Biol, 2005. 3(3): p. e85.
59.Sempere, L.F., et al., Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res, 2007. 67(24): p. 11612-20.
60.Iorio, M.V., et al., MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005. 65(16): p. 7065-70.
61.Fukushima, T., H. Takeshima, and H. Kataoka, Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res, 2009. 29(11): p. 4845-54.
電子全文 電子全文(網際網路公開日期:20250201)
連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top